Free Trial

Amit Gupta Sells 68,685 Shares of Cardlytics (NASDAQ:CDLX) Stock

Cardlytics logo with Business Services background

Key Points

  • Cardlytics CEO Amit Gupta sold 68,685 shares of the company's stock for a total of $76,927.20, resulting in a 12.26% decrease in his ownership position.
  • Following recent trading, Cardlytics shares have seen a price decline, trading at $1.10 with a market cap of $58.56 million.
  • Analysts have lowered their price targets for Cardlytics, with Lake Street Capital decreasing it from $3.00 to $2.50 and Evercore ISI reducing it from $3.00 to $2.00, reflecting a more cautious outlook.
  • Five stocks to consider instead of Cardlytics.

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 68,685 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.12, for a total transaction of $76,927.20. Following the sale, the chief executive officer owned 491,759 shares of the company's stock, valued at approximately $550,770.08. The trade was a 12.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Amit Gupta also recently made the following trade(s):

  • On Monday, August 18th, Amit Gupta sold 68,260 shares of Cardlytics stock. The stock was sold at an average price of $1.12, for a total value of $76,451.20.
  • On Wednesday, July 2nd, Amit Gupta sold 6,725 shares of Cardlytics stock. The stock was sold at an average price of $1.78, for a total value of $11,970.50.

Cardlytics Trading Up 9.9%

Shares of NASDAQ CDLX traded up $0.10 during mid-day trading on Friday, reaching $1.11. 807,503 shares of the company's stock were exchanged, compared to its average volume of 1,447,929. The firm has a market capitalization of $59.10 million, a price-to-earnings ratio of -0.30 and a beta of 1.26. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.16 and a current ratio of 1.16. Cardlytics, Inc. has a 52-week low of $0.95 and a 52-week high of $5.2450. The company's 50-day moving average is $1.74 and its 200-day moving average is $1.95.

Institutional Trading of Cardlytics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDLX. Geode Capital Management LLC raised its holdings in Cardlytics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company's stock worth $3,936,000 after purchasing an additional 7,561 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Cardlytics by 46.0% during the fourth quarter. Wells Fargo & Company MN now owns 21,106 shares of the company's stock worth $78,000 after purchasing an additional 6,649 shares in the last quarter. Barclays PLC raised its holdings in Cardlytics by 26.2% during the fourth quarter. Barclays PLC now owns 73,255 shares of the company's stock worth $272,000 after purchasing an additional 15,229 shares in the last quarter. XTX Topco Ltd acquired a new stake in Cardlytics during the fourth quarter worth approximately $157,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Cardlytics during the fourth quarter worth approximately $84,000. Institutional investors and hedge funds own 68.10% of the company's stock.

Wall Street Analysts Forecast Growth

CDLX has been the subject of a number of research analyst reports. Lake Street Capital lowered their target price on Cardlytics from $3.00 to $2.50 and set a "hold" rating for the company in a report on Thursday, May 8th. Evercore ISI lowered their target price on Cardlytics from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $2.25.

View Our Latest Stock Report on Cardlytics

About Cardlytics

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.